Literature DB >> 31465837

Colon-specific microspheres loaded with puerarin reduce tumorigenesis and metastasis in colitis-associated colorectal cancer.

Xiao-Qing Deng1, Hong-Bo Zhang2, Gui-Fang Wang1, Dong Xu1, Wen-Yan Zhang1, Qiang-Song Wang3, Yuan-Lu Cui4.   

Abstract

Colitis-associated colorectal cancer (CAC) is a common malignancy that develops in chronically inflamed mucosa and is usually accompanied by metastases at other sites. Puerarin, a natural isoflavone isolated from the root of the Pueraria lobata (Willd.) Ohwi, has potential anti-colon cancer activity. However, the poor solubility and low bioavailability of puerarin has restricted its application in the pharmaceutical industry. In the present study, pH-responsive alginate microspheres loaded with puerarin were prepared by emulsification/internal gelation for targeted treatment of colitis-associated colorectal cancer. Herein, puerarin, as an active drug, could participate in the construction of alginate microspheres with hydrogen bonding. The microspheres exhibited pH-responsive release behavior with little release of puerarin in simulated gastric fluid and high amounts (approximately 55%) of release in simulated colonic fluid. A fluorescence tracer indicated microspheres had high retention time of more than 20 h in the colon. Meanwhile, puerarin-loaded alginate microspheres not only significantly decreased the inflammatory response by downregulating the levels of pro-tumorigenic cytokines, but they reduced tumorigenesis and metastasis by inhibiting epithelial-mesenchymal transitions in AOM/DSS-induced colitis-associated colorectal cancer in mice. The overall results suggested that puerarin-loaded alginate microspheres could effectively inhibit development of colonic tumors, which could be developed as a promising therapeutic strategy for colitis-associated colorectal cancer.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Colitis-associated colorectal cancer; Colon-specific drug delivery; Microspheres; Puerarin; pH-responsive

Mesh:

Substances:

Year:  2019        PMID: 31465837     DOI: 10.1016/j.ijpharm.2019.118644

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Mucus-Penetrating Alginate-Chitosan Nanoparticles Loaded with Berberine Hydrochloride for Oral Delivery to the Inflammation Site of Ulcerative Colitis.

Authors:  Lingfeng Sun; Xiangjiang Nie; Wenjie Lu; Qing Zhang; Wenyou Fang; Song Gao; Shengqi Chen; Rongfeng Hu
Journal:  AAPS PharmSciTech       Date:  2022-06-27       Impact factor: 4.026

2.  Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways.

Authors:  Long Xiao; Mengdan Zhong; Yu Huang; Jie Zhu; Wenkai Tang; Danyong Li; Jiandong Shi; Aiqing Lu; Huilin Yang; Dechun Geng; Hong Li; Zhirong Wang
Journal:  Aging (Albany NY)       Date:  2020-11-07       Impact factor: 5.682

3.  Alginate nanogels-based thermosensitive hydrogel to improve antidepressant-like effects of albiflorin via intranasal delivery.

Authors:  Dong Xu; Tao Qiao; Yue Wang; Qiang-Song Wang; Yuan-Lu Cui
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

4.  Identification of the potential mechanism of Radix pueraria in colon cancer based on network pharmacology.

Authors:  Yi Li; Chunli Zhang; Xiaohan Ma; Liuqing Yang; Huijun Ren
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.996

5.  Composite Central Face Design-An Approach to Achieve Efficient Alginate Microcarriers.

Authors:  J F A Valente; J R Dias; A Sousa; N Alves
Journal:  Polymers (Basel)       Date:  2019-11-27       Impact factor: 4.329

Review 6.  New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy.

Authors:  Adrian H Teruel; Isabel Gonzalez-Alvarez; Marival Bermejo; Virginia Merino; Maria Dolores Marcos; Felix Sancenon; Marta Gonzalez-Alvarez; Ramon Martinez-Mañez
Journal:  Int J Mol Sci       Date:  2020-09-05       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.